AI Unlocks Prostate Cancer Treatment Benefits - Video

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer. The study involved ArteraAI, a developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and other researchers including those from University Hospitals (UH) Seidman Cancer Center. The information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

The study used novel deep learning methodology and histopathology image data from more than 5,000 patients across five Phase 3 randomized trials, with long-term follow-up. Patients in these trials were enrolled from over 100 centers across the US and Canada. The predictive AI biomarker was developed using datasets comprising about 20% African American patients. In past U.S.-based clinical trials, African American men have made up only 10.8% of prostate cancer trial participants.

In patients with localized prostate cancer, ADT can be added to radiotherapy if improved patient outcomes are anticipated. Some studies suggest many men do not need ADT as part of their treatment plan, and that radiotherapy alone is effective. If given the opportunity to leverage the biomarker, most intermediate-risk patients could potentially avoid the morbidity and financial burden associated with ADT.

Ref: Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer, NEJM Evidence, DOI 10.1056/EVIDoa2300023